Lipocine Announces Presentation of LPCN 1021 Clinical Data at ENDO 2015

Lipocine Inc.

, a specialty pharmaceutical company, today announced that data from its ongoing Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02081300) evaluating efficacy and safety of LPCN 1021, an Oral Testosterone product, in hypogonadal men with low testosterone ("Low T") will be presented at ENDO 2015 in San Diego, CA. As previously announced, overall, the study demonstrated positive results with respect to the trial's primary efficacy endpoint with no drug related serious adverse events to date. Presentation details are as follows: Session: Testosterone Replacement Therapy: Risks and Benefits Title: Efficacy and Pharmacokinetics of LPCN 1021, a Novel Oral Testosterone Replacement Therapy (TRT) in Hypogonadal Men: Study of Androgen Replacement (SOAR) Date/Time: Saturday, March 7, 2015, 11:30 am – 1:00 pm PT Oral Session Number: OR34-5 Presenter: Christina Wang, MD Associate Director UCLA Clinical and Translational Science Institute Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute Professor of Medicine David Geffen School of Medicine at UCLA